Results 41 to 50 of about 91,424 (147)
Loss of TRIM21 drives UVB‐induced systemic inflammation by regulating DNA‐sensing pathways
Arthritis &Rheumatology, Accepted Article.Background
Patients with systemic lupus erythematosus (SLE) experience photosensitivity, with exposure to ultraviolet light B (UVB) driving lupus flares and triggering symptoms like joint pain, fatigue, and cutaneous lesions. Although the mechanism(s) linking UVB exposure to systemic effects are unclear, type I interferons (IFNs) are known to play a ...Gantsetseg Tumurkhuu, Graziela Perri, Richard Moore, Lihong Huo, Arati Naveen Kumar, Richard Ainsworth, Trinitee Oliver, Gabriela de los Santos, David Gibb, Jessica Carriere, Jeong Min Yu, Rachel Abuav, Lindsy Forbess, Daniel J. Wallace, Mariko Ishimori, Wonwoo Shon, Christian Stehlik, Caroline A. Jefferies +17 morewiley +1 more sourceThymidine Phosphorylase Inhibitory Potential and Molecular Docking Studies of Secondary Metabolites Isolated From Fernandoa adenophylla (Wall. ex G. Don) Steenis
Chemistry &Biodiversity, EarlyView.ABSTRACT
This study investigates the potential of Fernandoa adenophylla, a South American plant, as a reservoir of compounds with thymidine phosphorylase (TP) inhibitory activity. Through a comprehensive approach combining in vitro assays and molecular docking analysis, we isolated and characterized bioactive compounds from F.Abdur Rauf, Majid Khan, Umer Rashid, Anees Saeed, Zafar Ali Shah, Zubair Ahmad, Abdulhakeem S. Alamri, Walaa F. Alsanie, Imtiaz Khan, Humaira Hussain, Majid Alhomrani, Marcello Iriti +11 morewiley +1 more sourceTaste Profile and Relative Bioavailability of Tovorafenib Powder for Oral Suspension and Food Effect of the Tovorafenib Tablet in Healthy Participants
Clinical Pharmacology in Drug Development, EarlyView.Abstract
A pediatric‐friendly powder for oral suspension (PfOS) of tovorafenib, a type II RAF inhibitor, was developed for patients with difficulty swallowing tablets. This open‐label, randomized, phase 1 study (QSC205140) evaluated the taste/palatability of PfOS formulations (n = 12), the relative bioavailability of the PfOS versus tablet formulation, Yang Zhang, Mike Preigh, Jing Wang, Eleni Venetsanakos, Yujin Wang, Elly Barry, Don Corson +6 morewiley +1 more sourcePlasma metabolomics identifies signatures that distinguish heart failure with reduced and preserved ejection fraction
ESC Heart Failure, EarlyView.Abstract Aims
Two general phenotypes of heart failure (HF) are recognized: HF with reduced ejection fraction (HFrEF) and with preserved EF (HFpEF). To develop phenotype‐specific approaches to treatment, distinguishing biomarkers are needed. The goal of this study was to utilize quantitative metabolomics on a large, diverse population to replicate and ...Fawaz Naeem, Teresa C. Leone, Christopher Petucci, Clarissa Shoffler, Ravindra C. Kodihalli, Tiffany Hidalgo, Cheryl Tow‐Keogh, Jessica Mancuso, Iphigenia Tzameli, Donald Bennett, John D. Groarke, Rachel J. Roth Flach, Daniel J. Rader, Daniel P. Kelly +13 morewiley +1 more sourcePhase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses
Nature Network Boston, 2020 J. Barrett, Sandra Belij-Rammerstorfer, C. Dold, K. Ewer, P. Folegatti, Ciarán Gilbride, R. Halkerston, J. Hill, D. Jenkin, L. Stockdale, M. Verheul, P. Aley, B. Angus, D. Bellamy, E. Berrie, S. Bibi, M. Bittaye, Miles W. Carroll, Breeze E. Cavell, E. Clutterbuck, N. Edwards, A. Flaxman, Michelle Fuskova, A. Gorringe, B. Hallis, S. Kerridge, A. Lawrie, Aline Linder, Xinxue Liu, Meera Madhavan, R. Makinson, J. Mellors, A. Minassian, M. Moore, Y. Mujadidi, Emma L Plested, I. Poulton, M. Ramasamy, H. Robinson, C. Rollier, R. Song, M. Snape, R. Tarrant, Stephen Taylor, Kelly M. Thomas, M. Voysey, Marion E. E. Watson, D. Wright, Alexander D. Douglas, Catherine M. Green, A. Hill, T. Lambe, S. Gilbert, A. Pollard, Jeremy Jennifer Aabidah Elizabeth Lauren Rachel Carolina Aboagye Alderson Ali Allen Allen Anslow Arancibia-, J. Aboagye, Jennifer Alderson, Aabidah Ali, E. Allen, Lauren Allen, R. Anslow, C. Arancibia-Cárcamo, E. Arbe-Barnes, M. Baker, P. Baker, Natalie Baker, Ioana Baleanu, Eleanor Barnes, L. Bates, Alexander Batten, Kirsten Beadon, Rebecca Beckley, Amy Beveridge, K. Bewley, E. Bijker, L. Blackwell, C. Blundell, Emma Bolam, E. Boland, N. Borthwick, A. Boyd, T. Brenner, Philip Brown, Charlie Brown-O’Sullivan, Emily Brunt, J. Burbage, K. Buttigieg, N. Byard, Ingrid Cabrera Puig, Susana Camara, Michelangelo Cao, F. Cappuccini, M. Carr, Miles W. Carroll, Jim Chadwick, I. Chelysheva, J. Cho, L. Cifuentes, Elizabeth Clark, Rachel Colin-Jones, C. Conlon, N. Coombes, R. Cooper, Wendy E. M. Crocker, C. Cunningham, B. Damratoski, M. Datoo, C. Datta, H. Davies, T. Demissie, Claudio Di Maso, Danielle DiTirro, T. Dong, F. Donnellan, N. Douglas, Charlotte Downing, Jonathan Drake, R. Drake-Brockman, R. Drury, S. Dunachie, Omar El Muhanna, Sean C. Elias, M. Elmore, Katherine Emary, M. English, S. Felle, S. Feng, Carla Ferreira Da Silva, Samantha M. Field, Richard Fisher, K. Ford, J. Fowler, E. Francis, J. Frater, J. Furze, Pablo Galian-Rubio, Harriet Garlant, K. Godwin, Giacomo Gorini, Lara Gracie, Gaurav Gupta, Elizabeth M Hamilton, Joseph Hamlyn, Brama Hanumunthadu, S. Harris, D. Harrison, Thomas C. Hart, Sophia Hawkins, J. Henry, Gina Hodges, S. Hodgson, M. Hou, Elizabeth Howe, Nicola J. Howell, Ben Huang, H. Humphries, Poppy Iveson, Susan A. Jackson, Frederic Jackson, Sam Jauregui, K. Jeffery, E. Jones, Kathryn L. Jones, Reshma Kailath, J. Keen, Sarah Kelly, D. Kelly, Elizabeth J Kelly, D. Kerr, Liaquat A. Khan, B. Khozoee, Annabel Killen, J. Kinch, T. King, L. King, Lucy Kingham-Page, P. Klenerman, J. Knight, Daniel Knott, S. Koleva, Colin Larkworthy, Jessica P. J. Larwood, E. Lees, Alice Lelliott, Stephanie Leung, Yuanyuan Li, A. M. Lias, Samuel Lipworth, Shuchang Liu, L. Loew, R. Lopez Ramon, Garry Mallett, Kushal Mansatta, Natalie Marchevsky, S. Marinou, E. Marlow, Julia L Marshall, P. Matthews, Joanne Mcewan, J. McGlashan, Lorna McInroy, Gretchen Meddaugh, A. Mentzer, N. Mirtorabi, E. Morey, R. Morgans, S. Morris, Hazel Morrison, Gertraud Morshead, R. Morter, Nathifa Moya, E. Mukhopadhyay, Jill Muller, C. Munro, Sarah Murphy, Philomena Mweu, Andrés Noé, F. L. Nugent, Elizabeth Nuthall, Katie O’Brien, D. O’Connor, D. O’Donnell, B. Oguti, Victoria Olchawski, Catarina Oliveria, P. O'reilly, P. Osborne, N. Owino, Kaye Parker, Helena Parracho, Maia Patrick-Smith, Yanchun Peng, E. Penn, Marco Polo Peralta Álvarez, James Perring, C. Petropoulos, K. Pfafferott, D. Pipini, Daniel Phillips, Pamela C. Proud, S. Provstgaard-Morys, D. Pulido, K. Radia, Durga Rajapaksa, F. Ramos Lopez, H. Ratcliffe, T. Rawlinson, Emilia Reyes Pabon, S. Rhead, A. Ritchie, H. Roberts, S. Roche, Indra Rudiansyah, Stephannie Salvador, H. Sanders, Katherine Sanders, I. Satti, A. Schmid, E. Schofield, G. Screaton, Cynthia Sedik, Imam Shaik, H. Sharpe, Adam Shea, S. Silk, L. Silva-Reyes, D. Skelly, Catherine C Smith, David J. Smith, Alexandra J. Spencer, E. Stafford, Anna Szigeti, A. Tahiri‐Alaoui, R. Tanner, I. Taylor, K. Taylor, Rebecca te Water Naude, Y. Themistocleous, Andreas C Themistocleous, Merin Thomas, Tonia Thomas, A. Thompson, Lan Tinh, A. Tomic, S. Tonks, James Towner, Nguyen H. Tran, J. Tree, Adam Truby, Cheryl Turner, N. Turner, M. Ulaszewska, R. Varughese, I. Vichos, Laura L Walker, M. Wand, C. White, Rachel White, P. Williams, A. Worth, T. Wrin, X. Yao, Dalila Zizi +302 moresemanticscholar +1 more sourcePre‐admission beta‐blocker therapy and outcomes in cardiogenic shock: Insights from the Altshock‐2 Registry
ESC Heart Failure, EarlyView.Among 668 with cardiogenic shock included in the multicentre prospective Altshock‐2 registry, 299 patients (44.8%) received pre‐admission beta‐blocker therapy. Previous beta‐blocker therapy influenced the early hemodynamic response to vasoactive drugs, but it was not associated with in‐hospital mortality.Matteo Pagnesi, Mauro Riccardi, Alice Sacco, Giovanni Tavecchia, Giovanna Viola, Simone Frea, Martina Briani, Letizia Fausta Bertoldi, Maurizio Bertaina, Luciano Potena, Serafina Valente, Marco Marini, Gaetano Maria De Ferrari, Nicoletta D'Ettore, Astrid Cardinale, Rita Camporotondo, Matteo Rota, Guido Tavazzi, Nuccia Morici, Federico Pappalardo, Marco Metra, on behalf of the
Altshock‐2 investigators +21 morewiley +1 more sourceCardioprotective effects of semaglutide on isolated human ventricular myocardium
European Journal of Heart Failure, EarlyView.Semaglutide reduces late sodium current (INa) and diastolic calcium (Ca) sparks in human cardiomyocytes from aortic stenosis (AS) and end‐stage heart failure with reduced ejection fraction (HFrEF) patients, thereby increasing Ca transients. Improved Ca storage may underly the enhanced contractility of human cardiomyocytes upon semaglutide.Thomas Krammer, Maria J. Baier, Philipp Hegner, Tilman Zschiedrich, David Lukas, Matthias Wolf, Christian Le Phu, Vanessa Lutz, Katja Evert, Kostiantyn Kozakov, Jing Li, Andreas Holzamer, Lars S. Maier, Zdenek Provaznik, Donald M. Bers, Stefan Wagner, Julian Mustroph +16 morewiley +1 more source